Transglutaminase 2 interacts with syndecan-4 and CD44 at the surface of human macrophages to promote removal of apoptotic cells  by Nadella, Vinod et al.
Biochimica et Biophysica Acta 1853 (2015) 201–212
Contents lists available at ScienceDirect
Biochimica et Biophysica Acta
j ourna l homepage: www.e lsev ie r .com/ locate /bbamcrTransglutaminase 2 interacts with syndecan-4 and CD44 at the surface of
human macrophages to promote removal of apoptotic cellsVinod Nadella a,b, Zhuo Wang a,b, Timothy S. Johnson c, Martin Grifﬁn a,b,⁎, Andrew Devitt a,b,⁎⁎
a School of Life & Health Sciences, Aston University, Birmingham B4 7ET, UK
b Aston Research Centre for Healthy Ageing, Aston University, Birmingham B4 7ET, UK
c Academic Nephrology Unit (Shefﬁeld Kidney Inst.), School of Medicine, University of Shefﬁeld, Beech Hill Rd., Shefﬁeld S10 2RZ, UKAbbreviations: AC, apoptotic cell; MØ, macrophage
derived macrophage; TG2, transglutaminase-2; SDC4
recognitionreceptor;MDC,monodansylcadaverine;HSPG,
HS, heparan sulphate; PMA, phorbol 13-myristate 12-acet
gplTG, guinea pig liver transglutaminase; HRP, horseradis
matrix; BTC, biotin-cadaverine
⁎ Correspondence to: M. Grifﬁn, School of Life & Hea
Birmingham, UK. Tel.: +44 121 204 3942; fax: +44 121
⁎⁎ Correspondence to: A. Devitt, School of Life & Hea
Birmingham, UK. Tel.: +44 121 204 4165; fax: +44 121
E-mail addresses:m.grifﬁn@aston.ac.uk (M. Grifﬁn), a
http://dx.doi.org/10.1016/j.bbamcr.2014.09.020
0167-4889/© 2014 Elsevier B.V. All rights reserved.a b s t r a c ta r t i c l e i n f oArticle history:
Received 2 May 2014
Received in revised form 7 September 2014
Accepted 19 September 2014
Available online 29 October 2014
Keywords:
Macrophages
Transglutaminase 2
Syndecan 4
CD44
Apoptotic cell clearance
Heparan sulphate proteoglycanTissue transglutaminase (TG2) is a multifunctional protein cross-linking enzyme that has been implicated in
apoptotic cell clearance but is also important in many other cell functions including cell adhesion, migration
and monocyte to macrophage differentiation. Cell surface-associated TG2 regulates cell adhesion and migration,
via its association with receptors such as syndecan-4 and β1 and β3 integrins. Whilst defective apoptotic cell
clearance has been described in TG2-deﬁcient mice, the precise role of TG2 in apoptotic cell clearance remains
ill-deﬁned. Our work addresses the role of macrophage extracellular TG2 in apoptotic cell corpse clearance.
Here we reveal TG2 expression and activity (cytosolic and cell surface) in humanmacrophages and demonstrate
that inhibitors of protein crosslinking activity reducemacrophage clearance of dying cells.We showalso that cell-
impermeable TG2 inhibitors signiﬁcantly inhibit the ability of macrophages to migrate and clear apoptotic cells
through reduced macrophage recruitment to, and binding of, apoptotic cells. Association studies reveal TG2–
syndecan-4 interaction throughheparan sulphate side chains, and knockdown of syndecan-4 reduces cell surface
TG2 activity and apoptotic cell clearance. Furthermore, inhibition of TG2 activity reduces crosslinking of CD44, re-
ported to augment AC clearance. Thus our data deﬁne a role for TG2 activity at the surface of humanmacrophages
inmultiple stages of AC clearance and we propose that TG2, in association with heparan sulphates, may exert its
effect on AC clearance via a mechanism involving the crosslinking of CD44.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
Transglutaminases are a family of enzymes that catalyse covalent
bond formation between lysine and glutamine-residues in target pro-
teins leading to their post-translational modiﬁcation [1]. TG2 is the
most widely expressed family member [2] and is found both in the cy-
toplasm and extracellularly at the cell surface [3]. When externalized,
TG2 is found associated with integrins [4] and heparan sulphates (HS)
[5–8]. Following translocation to the cell surface, it is deposited into
the extracellular matrix [3]. Whilst protein cross-linking is the most
studied function of TG2, it also participates in other biological processes
unrelated to its transamidase activity [9] — e.g. cell adhesion through; HMDMØ, human monocyte-
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.devitt1@aston.ac.uk (A. Devitt).cell surface association with integrins [4] and syndecans [5,6,8,10,11].
However recent work has shown that the extracellular crosslinking
activity of TG2 is involved in S100A4-related cell migration involving a
syndecan-4 and β1 integrin co-signalling pathway [12].
Unwanted cells within the body are removed by apoptosis, a process
which culminates in apoptotic cell (AC) removal by professional phago-
cytes (macrophages) and accompanying anti-inﬂammatory responses
to prevent inﬂammatory and autoimmune conditions [13]. Removal of
AC is an integrated, multistep process that in vivo involves recruitment
of macrophages. This is followed by recognition and binding of cell
corpses prior to engulfment (phagocytosis) through the use of a range
of receptors and soluble bridging molecules to bind dying cell ligands
[14–17]. Tissue transglutaminase (TG2) has been shown to play an im-
portant role in this process.
Important previous work utilised TG2−/− mice to reveal defective
clearance of AC and reduced TGF-β1 with strong association with in-
ﬂammation and autoimmunity [18]. A further detailed study deﬁned a
role for cell surface TG2 in engulfment of AC through phagocytic portal
stabilisation [19]. In this context TG2was shown to function through the
interaction with β3 integrin and the AC opsonin MFG-E8. Despite this
signiﬁcant previous work, the molecular associations and function of
TG2 at the surface of human macrophages have not been fully deﬁned.
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human macrophages. Using a panel of TG2 inhibitors, including both
known cell-permeable and cell impermeable inhibitors, TG2 targeted
siRNA and an inhibitory antibody; we reveal a role of TG2 in the differ-
ent phases of AC clearance (phagocyte recruitment and AC tethering)
and also deﬁne the cellular site of action of TG2. Furthermore we dem-
onstrate for the ﬁrst time the importance of syndecan-4 in the macro-
phage cell surface localisation of TG2 which is required for efﬁcient
clearance of apoptotic cells. Recent studies have highlighted a role for
cross-linked macrophage CD44 in augmenting AC clearance [20]. Here
we further address the involvement of TG2 in interacting with CD44
to promote AC clearance.
2. Materials and methods
2.1. General reagents
The general reagents were purchased from Sigma-Aldrich (Poole,
UK), unless stated otherwise. Puriﬁed guinea pig liver transglutaminase
(gplTG), biotin-cadaverine (BTC) and the cell permeable TG2 inhibitor
Z-DON (Z-DON-Val-Pro-Leu-OMe) were purchased from Zedira (Darm-
stadt, Germany). The monoclonal TG2 activity-blocking antibody
D11D12 (GB patent ﬁling 1209096.5) was a kind gift from Dr. Tim
Johnson (Shefﬁeld University, UK). The TG2 inhibitor 1,3-dimethyl-2-
imidazolium derivative R283 [21] and the peptidic TG2 inhibitors
R294 and R281 were synthesized at Aston University [22,23]. Inhibitor
R281 is a membrane-impermeable, irreversible TG2 inhibitor [22,23].
R294 shows greater speciﬁcity for TG2 over other TG family members
[24] and is more water-soluble than R281 and is thus considered to be
similarly membrane impermeable [22]. Cell permeability of R283 has
not been formally demonstrated and Z-DON is reported to be cell per-
meable (Zedira). R281, R283 and R294 were used at 500 μM unless
otherwise stated. Monodansylcadaverine (MDC) was used at 100 μM.
The commercial antibodies used in this study are listed in Supple-
mentary Table 1. All blots were undertaken using the indicated mouse
monoclonal antibodies. Immunoﬂuorescence studies utilised either
mouse monoclonal or rabbit polyclonal antibodies as indicated.
2.2. Cell lines, cell isolation and culture
THP-1 (humanmyelomonocytic cell lines; ATCC) andMutu I BL [25]
were cultured in an RPMI-1640 medium (PAA, Yeovil, UK) containing
2 mM L-glutamine supplemented with 10% FCS (PAA, Yeovil, UK) and
100 IU/ml penicillin and 100 μg/ml streptomycin. Cells were cultured
at 37 °C in a humidiﬁed environment at 5% CO2.
Primary blood mononuclear cells were isolated from citrated blood
of healthy volunteers, following informed consent, by dextran sedimen-
tation and Percoll fractionation [26]. Monocyteswere allowed to adhere
to tissue culture wells (24 well plates) for 1 h prior to removal of other
cells by washing with serum-free RPMI. Isolated monocytes were cul-
tured for 7–8 days in a macrophage-SFM medium (Invitrogen Corp.,
Paisley, UK) at 37 °C in a 5% CO2 incubator [27].
2.3. THP-1 differentiation to macrophage-like cells
Differentiation of THP-1 into macrophage-like cells was induced by
treating THP-1 cells with 250 nM phorbol ester (PMA; Sigma, UK),
100 nM dihydroxyvitamin D3 (VD3; Enzo Life Sciences, UK) or both
(DS: double-stimulated) for 48–72 h at 37 °C in a 5% CO2 incubator in
growth medium. Differentiation was conﬁrmed by light microscopy
[28].
2.4. Apoptosis induction and quantiﬁcation
Mutu l (Burkitt's lymphoma cells)were exposed to 100 mJ/cm2 UV-B
irradiation, using a Chromata-vue C71 light box and UVX radiometer(UV-P Inc., Upland, CA, USA) and incubated for 16 h to allow apoptosis
to proceed [29]. For analysis of apoptotic nuclear morphology, cells
were ﬁxed in 1% (w/v) formaldehyde in PBS, stained with 4,6-
diamidino-2-phenylinole (DAPI, Sigma, 250 ng/ml in PBS) for 5 min
and observed using inverted epiﬂuorescence microscopy. For quantita-
tive analyses, cells stained for 5 min with acridine orange (Sigma,
10 μg/ml in PBS) were enumerated as a percentage of apoptotic cells
per total number of cells counted per sample using a Zeiss Axiovert
200M ﬂuorescence microscope (Carl Zeiss Ltd, Welwyn Garden City,
UK) and a Hamamatsu Orca camera driven by Volocity (Perkin-Elmer,
UK).
2.5. Annexin V labelling and ﬂow cytometry
UV irradiated Mutu BL were stained with annexin V-FITC
(eBiosciences Ltd., UK). Brieﬂy, cells were washed once by centrifu-
gation (200 ×g, 5 min) and resuspended in a binding buffer
(10 mM HEPES pH 7.4, 150 mM NaCl, 2.5 mM CaCl2) containing
annexin V-FITC (1 μl per 2 × 105 cells) for 15 min on ice. Following
washing once with binding buffer, cells were resuspended in 1 ml
of the binding buffer containing propidium iodide at a ﬁnal concen-
tration of 20 μg/ml. Samples were analysed immediately on a Quanta
SC ﬂow cytometer (Beckman Coulter, High Wycombe, UK). A mini-
mum of 5000 events was collected.
2.6. Assays of phagocyte interaction with apoptotic cells
Interaction (deﬁned as tethering plus phagocytosis) of apoptotic
Mutu by phagocytes (THP-1 derived macrophages, HMDMØ) was
carried out in 24-well plates [30]. Brieﬂy, phagocytes and AC at a ratio
of 1:100 were co-cultured for 1 h at 37 °C (for interaction) or 20 °C
(for tethering alone) in RPMI containing 0.2% (w/v) bovine serum albu-
min (Sigma). In assays using inhibitors (e.g. TG2 inhibitors, P1 peptide),
macrophages were treatedwith appropriate concentrations of inhibitors
in serum-free RPMI for 1 h before and throughout the co-culturing with
apoptotic cells (2 h total). Unbound apoptotic cells were removed by
extensive washing with PBS and cells ﬁxed with 1% (w/v) formaldehyde
in PBS. Cells were stained with DiffQuick II (Medion Diagnostics GmbH,
Switzerland) for 2 min, the stain replaced with PBS and cells scored by
light microscopy for the percentage of macrophages interacting with
apoptotic cells. At least 200macrophageswere scored in each of the trip-
licate wells per experiment and at least three independent replicates
were undertaken. For the assay of only tethering of AC to macrophages
(i.e. excluding phagocytosis), co-culturing was carried at room tempera-
ture (20 °C), a temperature non-permissive for phagocytosis [29].
2.7. Western blotting
Cells were washed with ice-cold PBS, pH 7.4 and lysed with a cell
lysis buffer (50 mM Tris–HCl, pH 7.4, containing 1% (v/v) Nonidet,
0.5% (w/v) sodium deoxycholate, 0.1% (w/v) SDS, 1 mM benzamidine,
1 mM NaF, 1 mM Na3VO4, 0.1 mM phenylmethylsulphonyl ﬂuoride
(PMSF) and a 1% (v/v) protein inhibitor cocktail (Sigma)). Protein quan-
tity in samples was estimated by the DC™-protein assay (detergent-
compatible, Biorad). Following protein quantiﬁcation, lysates contain-
ing 50 μg of proteinwere dissolvedwith an equal volume of 2× Laemmli
buffer (Sigma), heated to 95 °C for 5 min and resolved by standard
SDS-polyacrylamide gel electrophoresis. Following electro-blotting to
nitrocellulose (0.45 μm; GE Healthcare, UK), membranes were blocked
with 5% w/v non-fat milk in TBS–Tween (50 mM Tris, 150 mM NaCl,
0.05% v/v Tween 20; pH 7.4) and probed using speciﬁc primary mouse
monoclonal antibodies (1:1000 dilution; Supplementary Table 1).
Anti-mouse secondary antibody (1:2000 dilution; GE Healthcare)
conjugated with horseradish peroxidise (HRP) was used to detect pri-
mary antibodies. Detectionwas carried out by using ECL chemilumines-
cence (GE Healthcare, UK). Equal loading was veriﬁed by using mouse
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undertaken using densitometry where appropriate.
2.8. Heparinase-treatment of cell surface proteins
Heparan sulphate side chainswere removed from the surface of cells
by treatment of cells with heparinase II or, as a control, chondroitinase.
Brieﬂy, THP-1-derived macrophages were treated with heparinase II
(5 units/ml) or chondroitinase (5 units/ml) in serum-free RPMI (1 h,
37 °C). Following incubation cells were washed three times with a
complete culture medium (RPMI supplemented with serum) prior
to use in further experiments (e.g. assays of macrophage function
for AC interaction).
2.9. Isolation of cell surface proteins using biotinylation
Biotinylation of cell surface proteins was carried out, to permit puri-
ﬁcation and assessment of cell surface proteins in isolation from other
cell components, as described previously [6]. Brieﬂy, cells were rinsed
with ice-cold PBS (pH 8.0) and were labelled with 0.8 μM Sulfo-NHS-
LC-biotin (Pierce) dissolved in PBS (pH8.0) at 4 °C for 20min. Following
washingwith 50mMTris–HCl (pH 8.0) cells were lysed in 1% (w/v) SDS
in PBSwith benzonase (1:1000 of 250U/μl) for 30min on ice. Cell lysates
containing 600 μg of protein, following centrifugation at 13,000 ×g
for 20 min to remove non-broken cells, were added to 50 μl Neutr-
Avidin-Agarose resin beads (Pierce) which were initially washed
with PBS supplemented with 1% (w/v) BSA and incubated at 4 °C
overnight on a rotating platform. After washing with PBS, resin bead
bound biotin-labelled cell surface proteins were extracted by boiling
with the 2× Laemmli buffer and analysed by western blotting. A non-
biotinylated cell sample was also run to ensure that the pulldown was
speciﬁc only for cell surface biotinylated TG2 (Supplementary Fig. 1A).
2.10. Co-immunoprecipitation to study protein association
Co-immunoprecipitation to detect interaction between proteinswas
carried out as described previously [11]. Brieﬂy, cell lysates (equivalent
of 150 μg of protein)were pre-cleared by the addition of 50 μl ofwashed
protein-G-Sepharose beads (GE Healthcare) for 1 h prior to bead re-
moval by centrifugation (13,000 ×g, 10 min). Approximately 0.5 μg of
appropriate mouse monoclonal antibody was added to pre-cleared
cell lysates and incubated for 90 min at 4 °C on a rocking platform to
form immunocomplexes with the respective protein of interest.
Immunocomplexes were pulled down by incubating with protein-G-
Sepharose beads (50 μl), the beads washed in PBS three times prior to
harvest by centrifugation. Immunocomplexes were subsequently col-
lected via boiling in 30 μl of 2× Laemmli buffer. Immunocomplexes
with an isotype control antibody (mouse IgG1/kappa: MoPC21) were
also pulled down as a known negative control to exclude the possibility
that the protein of interest is binding non-speciﬁcally to beads or anti-
body. Immunoprecipitated proteins were separated using SDS-PAGE
and detected via western blotting by using speciﬁc antibodies.
2.11. Assessment of cell surface TG2 activity via biotin cadaverine
incorporation
Measurement of TG2 activity via biotin cadaverine incorporation
into ﬁbronectin was carried as described previously [5,11] with minor
modiﬁcations. Brieﬂy, a 96-well plate was coated with 5 μg/ml of ﬁbro-
nectin in wash buffer (50 mM Tris–HCl, pH 7.4) overnight at 4 °C. After
rinsingwells with 50mMTris–HCl (pH 7.4) and blockingwith 3% (w/v)
BSA in 50 mM Tris–HCl, pH 7.4 (30 min, 37 °C), cells were seeded into
the wells at 2 × 104 per well in serum-free RPMI medium containing
0.132 mM biotin-cadaverine. Wells with 100 ng of gplTG with 10 mM
Ca2+ or 10mMEDTA are used as positive and negative controls, respec-
tively. Following incubation for 2 h at 37 °C (in the presence ofinhibitors as appropriate to the individual experiment), the reaction
was terminated by the addition of 2 mM EDTA in PBS, pH 7.4 and the
cells were removed by 0.1% (w/v) deoxycholate in 2 mM EDTA in PBS,
pH 7.4. After rinsing wells with wash buffer and blocking with 3% (w/
v) BSA in 50 mM Tris–HCl, pH 7.4 for 30 min at 37 °C, biotin-
cadaverine incorporated into ﬁbronectin was detected by incubating
at 37 °C for 1 h with blocking buffer conjugated with HRP-conjugated
Extr-avidin (1:1000; Sigma-Aldrich, UK). HRP was detected using OPD
(Sigma) and colour development was terminated by the addition of
50 μl of 2.5 M H2SO4. The absorbance was measured at 492 nm.
Similarly, biotin cadaverine incorporation into TG2–CD44 cross-
linking was also carried out, where 1 × 105 THP-1/DS MØ was pre-
incubated with 8 μM biotin-cadaverine in the presence or absence of
non cell-permeable TG2 inhibitor R281 in a serum-free RPMI medium
at 37 °C for 2 h.Where R281 was used, MØ was pre-treated with an in-
hibitor for 1 h prior to the addition of BTC. Following BTC incorporation,
cell lysates equivalent to 150 μg protein were subject to pulldown of
biotin-containing molecules by Neutr-Avidin-Agarose resin beads. The
pulldowns were probed by western blotting for CD44 to reveal TG2-
mediated BTC incorporation into CD44.
2.12. Chemotaxis and migration studies
MØ chemotaxis towards AC was studied using a Dunn chemotaxis
chamber (Hawksley, Sussex) in conjugation with time-lapse microsco-
py [31]. This horizontal migration chamber establishes a true gradient
of attractant rather than the ‘step gradient’ associated with use of
vertical transwell-based systems. THP-1/DS cells, treated as appropriate
with cell-impermeable TG2 inhibitor R281 (1 h in serum-free RPMI
medium), were detached into 5 mM EDTA in PBS at 37 °C and reseeded
to plastic cover slips. Following incubation at 37 °C for 20 min in RPMI,
the coverslip was inverted on a chemotaxis chamber and sealed in
position using waxwith chemoattractants in the outer well. Cell migra-
tion was recorded using time-lapse microscopy (Zeiss Axiovert 200M
controlled by Improvision Volocity software). Quantitative assessment
of collected sequential images to allow mapping of individual cells
was carried out using Image J and the Ibidi Chemotaxis and Migration
tool (version 2.0, Ibidi), which provides measures of distance migrated
(Euclidian) and directness.
2.13. Immunoﬂuorescence staining
To detect cell surface proteins by indirect immunoﬂuorescence, cells
at 5 × 104 per well on multi-well glass slides (Hendley, Essex, UK) were
blocked with 3% (w/v) BSA in PBS (pH 7.4) for 30 min on ice. Following
washes with PBS, cells were incubatedwith primarymousemonoclonal
antibodies (1:100 dilution) or rabbit polyclonal antibodies (1:100
dilution), in serum-free RPMI for 2 h on ice. Cell washing with PBS,
pH 7.4 was followed by incubation with speciﬁc secondary antibody
reagents (anti-mouse or anti-rabbit as appropriate) conjugated with
either FITC or PE (1:100 dilution) for 2 h on ice. Stained cells were
washed twice with PBS, ﬁxed with 1% w/v formaldehyde in PBS and
mounted with Vectashield containing DAPI (Vector Laboratories).
Cells were examined using confocal microscopy (Leica Microsystems).
2.14. siRNA silencing of individual cellular components
Four different siRNAs targeting human syndecan-4 and another four
different siRNAs targeting TG2 were used to inhibit/knockdown the ex-
pression of both the proteins,while the non-silencing control siRNAwas
used as the negative control. All siRNAwere supplied at 10 μM(Qiagen).
Transfection was carried out according to manufacturer's protocol with
slightmodiﬁcations. Brieﬂy, 5 × 105 THP-1 cells were seeded (1.5ml) to
6-well plates andwere stimulatedwith PMA and VD3 to differentiate to
macrophage-like cells. Following 24 h of differentiation, cells were
transfected by the dropwise addition of 100 μl of transfection mix
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free RPMI). Following 48 h of incubation with the siRNA, whole cell ly-
sates were used to analyse the level of protein expression by western
blotting. Additionally cells at this same time point were used for
additional functional studies as appropriate.
2.15. Statistical analysis
Data are expressed as themean± S.E. for at least three independent
replicate experiments (n ≥ 3). Statistical tests were undertaken using
InStat (GraphPad, La Jolla, CA, USA). Statistical analysis of results was
undertaken using one-way analysis of variance (ANOVA) using a post-
test depending on the requirement.
3. Results
3.1. TG2 inhibitors reduce MØ–AC interaction through actions
on macrophages
Initial studies sought to address whether THP-1 cells, stimulated to
differentiate to MØ, express TG2 as this cell model provides a valuable
tool for undertaking many experiments in a controllable system. Thus
we undertook western blot analysis for TG2 on cell lysates of THP-1
cells (stimulated with dihydroxyvitamin D3, PMA or PMA/VD3) and
analysed for the presence of MØ cell surface TG2 following cell surface
biotinylation, We show that stimulated THP-1 cells (PMA or PMA/VD3)
express TG2 strongly and this expression includes cell surface expres-
sion (Fig. 1A and Supplementary Fig. 1A). Cell surface expression was
also clearly revealed with immunoﬂuorescence microscopy (Fig. 1A)
in PMA and PMA/VD3 cells but not in THP-1 cells or VD3 cells. The
lack of detectable cell surface TG2 in THP-1 cells or those stimulated
solely with VD3 is consistent with the lack of TG2 expression noted in
whole cell lysates.
To conﬁrm a role of TG2 in human MØ clearance of AC, THP-1 MØ
(THP-1/PMA, THP-1/VD3 and THP-1/DS) were treated initially with
TG2 inhibitors R283 & Z-DON (the latter is claimed to be cell perme-
able by the manufacturer Zedira) or R281 and R294 (R281 is cell-
impermeable [22,23] and R294 more water soluble and likely there-
fore to be similarly cell-impermeable [22]), irreversible TG2 site-
directed inhibitors [22]. The inhibitors were used at 500µM except
Z-DON which was used at 100µM. Following a 1 h inhibitor treat-
ment, macrophages were assessed for their ability to interact with
apoptotic B cells, where interaction is deﬁned as the sum of both
tethering (binding) and phagocytosis (engulfment) of AC. All four
TG2 inhibitors including the cell-impermeable inhibitors 281 and
294 reduced signiﬁcantly MØ–AC interaction in those MØ
that expressed TG2 (THP-1/PMA, THP-1/DS; Supplementary Fig. 2A),
suggesting that TG2 is mediating its actions at the cell surface. Further
studies revealed the inhibitor effects to be dose dependent (Fig. 2B
and Supplementary Fig. 2B) with no cellular toxicity (Supplementary
Fig. 3). AC clearance by phagocytes is a multistage process and to as-
sess the role of TG2 in the tethering of AC to MØ, TG2 inhibitors were
added to MØ–AC co-cultures at 20 °C, a temperature non-permissive
of phagocytosis [29]. Inhibition of cell tethering was shown by all the
TG2 inhibitors tested (Fig. 1C). Similarly, the inhibitors reduced AC
interaction with primary human monocyte-derived macrophages
(Fig. 1D).
In order to identify the cellular target of TG2 inhibition MØ or AC
were individually treated with TG2 inhibitors prior to co-culture. Treat-
ment of MØ led to the most profound reduction in MØ–AC interaction
(Fig. 1E), suggesting that the principal TG2 inhibition effect is on the
MØ not the AC, and that MØ TG2 is required for MØ–AC interaction.
This is further supported by TG2 expression studies (Supplementary
Fig. 3) since in leucocyte cells used as apoptotic targets, TG2 was not
detectable by western blot. These data support a prominent role of
TG2 in MØ–AC interaction in those highly differentiated human MØcells (HMDMØ, THP-1/PMA, THP-1/DS) but not in the monocyte-like
models (THP-1 and THP-1/VD3).
3.2. TG2 inhibitors reduceMØmigration towards AC-derivedmicroparticles
Macrophage migration to dying cells is an important event in vivo
for phagocytic removal of AC and MØ has been shown to migrate
towardsAC along a gradient of AC-derivedmicroparticles [29]. To deter-
mine the role of TG2 on MØ migration to AC, THP-1 cells double-
stimulated with PMA/VD3 (DS) were assessed for their migration
towards AC microparticles in the presence or absence of the TG2 cell-
impermeable inhibitor R281. Inhibition of TG2 resulted in a dramatic
loss of MØ migration towards AC (Fig. 2A), with a parallel effect on
MØ directionality (Fig. 2A). Direct (Euclidean) distance migrated
between start and end points and velocity ofmigration had reduced sig-
niﬁcantly with TG2 inhibitor treatment (Fig. 2B).
3.3. TG2 knockdown in MØ showed limited ability to interact with AC
To further conﬁrm a role of TG2 in MØ–AC interaction, THP-1 cells
were transfected with four different siRNA targeting human TG2,
while the global non-silencing (NS) siRNA was used as the control.
After stimulating THP-1 with PMA and VD3 for 24 h, cells were
transfected with siRNA for a further 48 h before whole cell lysates
were analysed by western blotting for TG2 expression (Fig. 3A). TG2
siRNA1 caused a reduction (approximately 70%) in TG2 expression, in
comparison to NS siRNA, and this TG2 knockdown reduced interaction
between siRNA1-treated macrophages and AC by around 50% when
compared to the inactive control siRNA transfected cells (Fig. 3B).
Importantly, the reduced MØ–AC interaction noted with either the
cell-impermeable TG2 inhibitor (R281) or siRNA knockdown of TG2,
acting either independently or in combination, could be partially
rescued by the addition of exogenous active TG2 (Fig. 3C) indicating
the speciﬁcity of action of the TG2 effects shown here and conﬁrming
that active TG2 at the MØ cell surface is important for apoptotic cell
clearance.
3.4. Cell surface TG2 protein cross-linking activity mediates
MØ–AC interaction
Site-directed TG2 irreversible inhibitors can block both the
transamidating activity and alter TG2 conformation by holding it in
its open conformation after reaction [32]. Such changes to TG2 con-
formation could affect binding of TG2 to its high afﬁnity ligands
such as heparan sulphates [6]. To address the involvement of TG2 ac-
tivity and/or conformation in MØ–AC interactions, the use of the
competitive primary amine substrate monodansylcadaverine (MDC)
at a concentration of 100 μM, which also blocks protein cross-linking
was used. MDC reduced MØ–AC interaction to the same degree as the
irreversible cell-impermeable inhibitor R281; suggesting that alter-
ations to TG2 activity, not conformation were responsible for altered
AC clearance (Fig. 4A).
Given that our results suggest that the activity of cell surface TG2 is
important in AC clearance, we next demonstrated the presence of
in situ cell surface TG2 activity in live cells (Fig. 4B) using established
techniques [5,11]. This activity was inhibited using our panel of TG-2
inhibitors. Add-back of puriﬁed exogenous active TG2 to the inhibi-
tor treated MØ resulted in a partial rescue of TG2 activity (Fig. 4B).
Primary human MØ showed a similar pattern of cell surface TG2 ac-
tivity (Supplementary Fig. 5). Additionally, TG2 knockdown by siRNA
resulted in the loss of cell surface TG2 activity (Fig. 4C) consistent with
reduced TG2 expression (Fig. 3A). Furthermore, a speciﬁcally targeted
TG2 activity-blocking antibody [33] inhibited MØ–AC interaction in a
dose-dependent manner (Fig. 4D). Taken together these data demon-
strate an important role for TG2 cross-linking activity at the surface of
human MØ in mediating AC removal.
Fig. 1. TG2 inhibitors reduce apoptotic cell clearance bymacrophages. (A)Western blot analysis revealing bothwhole cell lysate (WCL) and cell surface (CS) TG2 expression in THP-1 cell-
derived MØ (through stimulation with VD3, PMA or both (DS)) and primary HMDMØ. THP-1/PMA, THP-1/DS and HMDMØ but not undifferentiated THP-1 and THP-1/VD3 showed
detectable TG2 expression by western blotting (left panel). Cell surface TG2 was detected speﬁcally following cell surface protein biotinylation, prior to isolation of biotinylated proteins
using Neutr-Avidin as described in theMaterials andmethods section. Equal loading was veriﬁed by probingwithmouse anti-tubulin antibody on strippedmembranes. Similarly, surface
expression of TG2 in THP-1/DSwas revealed upon indirect immunoﬂuorescence staining of live (i.e. unpermeabilised) cells withmouse monoclonal anti-TG2 antibody (Cub7402) in con-
jugationwith FITC-conjugated anti-mouse secondary antibody (right panel). Nucleiwere stainedwithDAPI. The bar corresponds to 25 μm. (B)Dose-dependent effect of three site-directed
irreversible TG2 inhibitors on MØ (THP-1/DS) interaction with AC. Inhibitors were applied to MØ for 1 h prior to and throughout the co-culture with AC. ‘Interaction’ is deﬁned as the
combination of those AC tethered (bound) to the surface of MØ and those internalised (phagocytosed). (C) TG2 inhibitors (including cell-impermeable R281 and its more water soluble
counterpart R294) inhibitedMØ (THP-1/DS) tethering of AC (i.e. where only surface binding of AC toMØ is assayedwithout contribution fromphagocytic events) and, (D) a similar effect
of TG2 inhibitors is seen in HMDMØ interacting with AC. (E) Treatment of either MØ alone or AC alone with TG2 inhibitors showed signiﬁcant reduction in MØ–AC interaction following
inhibitor treatment of MØ. Data shown are mean ± S.E. for n ≥ 3 independent replicates. Statistical analysis was conducted using ANOVA followed by Bonferroni post-test (*P b 0.05;
***P b 0.001).
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Wenext investigated the involvement of TG2 binding partners at the
human MØ cell surface. In other cells, TG2 has been shown to have a
strong binding afﬁnity for heparan sulphates (HS) of the cell surface re-
ceptor syndecan-4 that is important in the translocation of TG2 to the
cell surface and extracellular matrix (ECM) [5,11]. Thus an attractive
candidate partner was syndecan-4, a heparan sulphate proteoglycan
(HSPG) that acts as a receptor for TG2 via its HS chains thus mediating
an RGD-independent cell adhesion via a TG2–FN complex [6]. Through
the use of western blotting and immunoﬂuorescence staining (Fig. 5A)we demonstrate a clear expression of syndecan-4 in THP-1/DS cells
that also shows a strong TG2 expression. To conﬁrm a possible interac-
tion between cell surface TG2 and syndecan-4, we performed co-
immunoprecipitation assays and demonstrate a TG2–syndecan-4
interaction in MØ cells (Fig. 5B and Supplementary Fig. 1B).
3.6. Loss of cell surface heparan sulphates or syndecan-4 reduces cell surface
TG2 expression and activity resulting in reduced MØ–AC interaction
HS on HSPGs (e.g. syndecan-4) mediate TG2 binding at cell surfaces
[5,11]. In order to test the importance of HS and syndecan-4 in
Fig. 2. TG2 inhibition reduces macrophage migration to AC. (A) The effect of TG2 inhibitor R281 on MØ (THP-1/DS) migration towards AC was tested using a Dunn chemotaxis chamber
coupled with time-lapse imaging phase contrast microscopy over 20 h. MØ were pre-treated for 1 h with the inhibitor prior to exposure to AC in a Dunn chamber. Cell migration was
tracked using ImageJ software and tracks were analysed using Chemotaxis and Migration Tool 2.0 (IBIDI), and were plotted as distance migrated (μm). The track of each cell is shown,
starting at the cross hairs and ﬁnishing at a dot, with the position of the attractant at the top of each plot. Representative plots are shown. R281, a cell-impermeable TG2 inhibitor induced
a dramatic reduction inMØmigration. A loss of directionality is shown in the rose diagram (insets). (B) The distancemigrated and the velocity at which the cells migrate in the presence
and absence of TG2 inhibitor (R281) are presented as mean ± S.E. for n ≥ 3 independent replicates. Statistical analysis was conducted using ANOVA followed by Bonferroni post-test
(**P b 0.01; ***P b 0.001).
206 V. Nadella et al. / Biochimica et Biophysica Acta 1853 (2015) 201–212presenting TG2 at the human macrophage cell surface where it medi-
ates AC clearance, we studied the effect of HS removal, syndecan-4
knockdown and blocking TG2–syndecan-4 binding on MØ–AC interac-
tion. Loss of HS, via heparinase II treatment, resulted in loss of cell sur-
face TG2 activity (Fig. 6A) and reduced MØ–AC interaction (Fig. 6B).
Using syndecan-4 speciﬁc siRNAs, a maximal reduction in SDC4 expres-
sion (approximately 60%) was obtained (Supplementary Fig. 6A)
resulting in reduced presence (Fig. 6C) and activity (Fig. 6D) of cell sur-
face TG2 though thiswas only evidentwith themost robust knockdown
of SDC4 provided by siRNA construct 2. This strongly suggests that cell
surface TG2 is anchored, at least in part, to syndecan-4, the loss of
which results in loss of cell surface TG2 activity. No loss of syndecan-4
expression is found in TG2 knockdown THP-1/DS (Supplementary
Fig. 6B) and total TG2 expression was unaffected by loss of syndecan-4
expression.
Syndecan-4 knockdown reduces MØ–AC interaction and when
syndecan-4 knockdown THP-1/DS cells were also treated with R281,
no further reduction in MØ–AC interaction occurs (Fig. 6E) suggesting
no additive effect and supporting the notion that the involvement of
syndecan-4 or TG2 in AC clearance is functionally related. These data
conﬁrm HS as prime receptors for TG2 binding on the MØ cell surface
and syndecan-4 as one HSPG important for TG2 binding.
To further strengthen our understanding of TG2–syndecan-4 bind-
ing via HS, we used the P1 peptide (200NPKFLKNAGRDCSRRSS216),
which mimics the heparin binding domain within TG2 and competes
for its binding to syndecan-4 [8]. Cells were treated with P1 peptide
or a scrambled control P1 peptide for 30 min and here we demon-
strate that the P1 peptide (but not the scrambled control peptide) re-
duces MØ–AC interaction (Fig. 6F) in a dose-dependent manner(Supplementary Fig. 6C). However, upon exogenous addition of ac-
tive TG2, the loss of MØ–AC interaction was found to be partially
compensated (Fig. 6F), suggesting that TG-2 bound to syndecan-4
via HS is crucial in mediating MØ–AC interaction.
3.7. TG2 interacts with CD44 at the MØ cell surface: A possible TG2
mediated CD44 cross-linking
CD44, an HSPG and established receptor for hyaluronan, is impor-
tant in immune cells' proliferation and differentiation, cell adhesion,
migration, and inﬂammation [34–36]. CD44 undergoes complex alter-
native mRNA splicing and posttranslational modiﬁcations resulting in
a family of isoforms with distinct biological functions [37]. CD44 is a
known phagocytic receptor [38] that, when cross-linked by antibody,
augments AC clearance [20]. We therefore investigated whether TG2
may mediate CD44 crosslinking to facilitate AC clearance.
Initially we examined CD44 expression and found it paralleled TG2
expression (Fig. 7A) in THP-1/DS, THP-1/PMA and HMDMØ. Interest-
ingly, two major distinct molecular weight bands for CD44 were
expressed. To address the possibility that the high molecular weight
CD44 is a TG2 cross-linked form (cross-linked to itself or other mole-
cules), CD44 expression in TG2 inhibitor-treated cells was examined.
Inhibition of TG2 was associated with a loss in the intensity of the
high molecular CD44 (~150 kDa) and an increase in the intensity of
low molecular weight CD44 (~85 kDa) consistent with the notion that
the high molecular weight CD44 species arises from TG2 activity
(Fig. 7B). Precipitation of TG2 resulted in the co-precipitation of CD44
(Fig. 7C) suggesting a possible TG2–CD44 interaction. Importantly, in
support of the small molecular CD44 species being a substrate of TG2
Fig. 3. Addition of exogenous active TG2 can compensate for the impaired macrophage–
apoptotic cell interaction seen with TG2 knockdown or inhibition. (A) Western blot anal-
ysis of TG2 expression using mouse anti-TG2 in THP-1/DS following transfection with the
indicated TG2-targeted siRNA constructs or a non-speciﬁc control (NS). A representative
blot is shown along with densitometric analysis from three independent experiments.
Statistics compare to NS control construct. (B) TG2 knockdown with siRNA 1 reduces
MØ (THP-1/DS) interaction with AC compared to cells similarly transfectedwith a control
siRNA (NS siRNA). (C) Reduced MØ–AC interaction as a result of TG2 knockdown (siRNA
1) or TG2 inhibition (R281) is rescued by the addition of exogenous active, but not inactive
TG2.Where appropriate, inhibitorswere applied toMØ for 1 h prior to and throughout the
co-culture with AC. Data shown are mean ± S.E. for n ≥ 3 independent replicates. Statis-
tical analysiswas conducted using ANOVA followed by Bonferroni post-test (***P b 0.001).
Fig. 4. TG2 activity promotes macrophage–apoptotic cell interaction.
(A) Monodansylcadaverine (MDC: inhibits crosslinking in the presence of Ca2+, as used
here, without changing the conformation of TG2) reduces MØ (THP-1/DS) interaction
with AC. Similar levels of inhibition are noted with irreversible TG2 inhibitor R281. All in-
hibitors were applied to MØ for 1 h prior to and throughout the co-culture with AC.
(B)MØ(THP-1/DS) cell surface TG activitywas assessed (via biotin-cadaverine incorpora-
tion intoﬁbronectin) followingMØtreatmentwith the indicated TG2 inhibitor and adding
active TG2 exogenously following R281 treatment. The positive control is gplTG. The
negative control comprises the addition of 10mMEDTA. (C) Cell surface transglutaminase
activity was similarly assessed in MØ transfected with the TG2-speciﬁc siRNA or a non-
speciﬁc control (NS siRNA). (D) TG2 binding antibody (D11D12) inhibits MØ–AC interac-
tion in a dose-dependent manner compared to the isotype control mAb MoPC21. Data
shown are mean± S.E. for n≥ 3 independent replicates. Statistical analysis was conduct-
ed using ANOVA followed by Bonferroni post-test (***P b 0.001).
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the presence of the high molecular weight CD44 species was barely
detectable in primary human macrophages (Fig. 7D).
To further conﬁrm that CD44 is a potential substrate of macrophage
cell surface TG2, THP-1/DSwere incubated with the TG2 primary amine
substrate biotin-cadaverine (BTC). Following cell lysis, proteins with
TG2 incorporated BTC were afﬁnity puriﬁed with Neutr-Avidin-
Agarose resin beads. Western blot analysis for CD44 revealed that
both high and low molecular weight bands for CD44 were present
(Fig. 8A). However, treatment with the TG2 irreversible inhibitor R281
prior to BTC incorporation resulted in a signiﬁcant loss in high molecu-
lar weight CD44 (Fig. 8A) conﬁrming that CD44 is a potential substrate
for cell surface TG2. Whilst R281 is an irreversible inhibitor of TG2, the
inhibition is incomplete (Fig. 4B) and this provides an explanation of
why there is BTC incorporation remaining even in the presence of TG2
inhibitors. The cell surface interaction of TG2 with CD44was conﬁrmed
by immunoﬂuorescence analysis of TG2 and CD44 which showed co-
localisation of CD44 with TG2, although not all TG2 showed co-
localisation with CD44 (Fig. 8B). This provides further evidence that
TG2 interacts with CD44 supporting both the co-immunoprecipitation
analysis and BTC incorporation studies.
To study the effect of TG2–CD44 interaction onMØ ability to interact
with AC, a MØ–AC interaction assay was performed following CD44knockdown in MØ. CD44 siRNA-9 caused a signiﬁcant reduction in
CD44 expression in comparison to NS siRNA (Supplementary Fig. 7A),
and loss of CD44 resulted in reduced MØ–AC interaction by around
40% when compared to the NS siRNA transfected cells (Fig. 8C). There
was no effect on cell surface TG2 expression (Supplementary Fig. 7B).
Interestingly, treating MØ with TG2 inhibitor R281 or treating CD44
siRNA-9 transfected MØ with R281 showed a further reduction in
the MØ–AC interaction, suggesting that TG2 can act independently of
CD44, possibly through syndecan 4.
4. Discussion
Phagocytic removal of apoptotic cells involves an array of phagocyte
receptors which, directly or indirectly via soluble bridging molecules,
facilitate recognition and binding of AC associated ligands ultimately
leading to corpse uptake [16,17]. As evident from previous studies
using TG2 deﬁcient mice, TG2 plays a prominent role in AC engulfment
by promoting phagocytic portal formation [18,19]. It is also crucially
important in immunemodulation to prevent inﬂammation and autoim-
munity [18]. Here we extend those studies to characterise TG2 in AC
clearance and address its location and function in humanmacrophages.
Using a TG2-inhibitor-based approach, rather than TG2-deﬁcient ani-
mals, we address TG2 in human cells that have developed in a TG2-
replete status before speciﬁcally inhibiting TG-2 activity or expression.
Fig. 5.Macrophage cell surface TG2 associates with syndecan-4. (A)Western blot analysis
(left panel) reveals the expression of syndecan-4 (detected with mouse anti-SDC4 mAb)
in undifferentiated and a panel of differentiated THP-1 MØ cells. Stripped membranes
were re-probed with mouse anti-α-tubulin antibody as a loading control. Similarly,
syndecan 4 expression at the cell surface of THP-1/DSMØwas detected using indirect
immunoﬂuorescence (mAb to syndecan-4; goat anti-mouse FITC) and confocal
imaging. (B) Interaction between TG2 and syndecan-4 in THP-1/DS MØ is revealed
by co-immunoprecipitation analyses. Syndecan-4 (SDC4) was precipitated using an
anti-SDC4 antibody. Precipitated material was separated by PAGE and co-precipitation of
TG2 assessed by anti-TG2western blotting (usingmouse anti-TG2mAb; anti-mouse-HRP).
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comprehensive view of TG2 function in AC clearance.
Our initial western blot studies addressedwhole cell and cell surface
TG2 expression in a panel of THP-1 cell-derived macrophage models
and HMDMØ. These cells expressed TG2 at the cell surface [39] with
the exception of THP-1 parental cells and THP-1/VD3 cells where TG2
was not detectable. Given the monocyte-like (relatively immature)
morphology of these cells [28], these data suggest that TG2 expression
is linked to monocyte/macrophage maturity [40,41].
Building on the important previous work in mice, we assessed TG2
in human MØ through the use of irreversible site-directed TG2 inhibi-
tors [22] including proven cell-permeable (Z-DON, Zedira) or cell-
impermeable (R281) inhibitors. All the inhibitors tested strongly re-
duced MØ–AC interaction (i.e. tethering and phagocytosis combined)
and tethering (binding alone) by those MØ that expressed TG2. Impor-
tantly, similar results were noted for primary human MØ. Detection of
TG-2 expression at the MØ surface coupled with the ability of cell-
impermeable inhibitors and a TG2-speciﬁc inactivating antibody to
reduce MØ–AC interaction suggests that MØ cell surface TG2 plays
a prominent role in MØ–AC interaction. To address the issue of
inhibitor-induced conformational changes of TG2, as an explanation
for reduced MØ–AC interaction, the competitive TG2-substrate MDC
was employed since it blocks TG2-induced protein crosslinking in
the presence of Ca2+without any irreversible change in TG2 conforma-
tion [32]. Again we demonstrated a signiﬁcant reduction in MØ–AC
interaction conﬁrming TG2 crosslinking activity as required for AC
clearance by humanmacrophages. This conclusion is further supported
by our use of siRNA to knockdown TG2 that resulted in reduced expres-
sion and cell surface activity of TG2. Taken together, with the ability
of the TG2 activity-blocking antibody to reduce MØ–AC interaction,
these data demonstrate for the ﬁrst time that TG2 on the surface of
human MØ is important in the tethering and removal of apoptotic
cells. Importantly we show a requirement for TG2 crosslinking activity
in this function. In addition to TG2, macrophages are known to expressFactor XIIIa (another TG family members) [42,40]. To rule out the in-
volvement of this enzyme in macrophage–AC interactions we used a
TG2-speciﬁc inactivating mAb. Additionally we used the irreversible
TG2 inhibitors R294 (that has an IC50 for Factor XIIIa of greater than
200 μM but has an IC50 for TG2 of 8 μM) and R281 (which also has an
IC50 for Factor XIIIa of greater than 100 μM but an IC50 for TG2 of
10 μM) [24]. In addition, we also used TG2 targeted siRNA. The use of
the inactivating TG2 mAb and the use of TG2 targeted siRNA will also
rule out the involvement of other possible isoforms of TG that might
be present.
Removal of AC in vivo is preceded by MØ migration to sites of cell
death [30]. Since TG2 cell surface activity has also been reported to be
important in cell migration [12,43] we investigated the ability of TG2
inhibitors to modulate MØ migration towards AC using a horizontal
migration chamber. We demonstrate that inhibition of TG2 reduces
both the velocity anddistancemigrated byMØ in response toAC and re-
sults in a complete loss of directionality. These data suggest that TG2 is
involved inMØmigration. As syndecan-4 is known to be a key signalling
receptor determining directional migration [44], loss of TG2 which is
known to be a strong binding partner would have resulted in loss of di-
rectional migration. However, it is unclear if this effect is mediated
through reduced cell adhesion or reduced detection of ‘ﬁndme’ signals
released from apoptotic cells and this requires further study.
In light of the importance of cell surface TG2 in our studies, we ad-
dressed the mechanism by which TG2 may arrive at the MØ surface.
Syndecan-4, a HSPG, has been shown to act, in non-MØ, as a receptor
for TG2 via its HS chains where it can mediate TG2 translocation to
the cell surface and ECM [5,11]. Here we demonstrate syndecan-4
expression in all our THP-1 cell-derived models, irrespective of their
TG2 expression. Through co-immunoprecipitation studies we demon-
strated that syndecan-4 interacts with TG2 (where expressed), consis-
tent with earlier studies [5,6,8,10]. Loss of syndecan-4 or cell surface
HS resulted in a signiﬁcant loss of cell surface TG2 expression and activ-
ity, affecting MØ–AC interaction. Interestingly, whilst two different
siRNA constructs for syndecan-4 resulted in reduced syndecan-4
expression, only the most robust blockade of syndecan-4 impacted on
surface TG2 expression and activity, possibly suggesting that a threshold
of syndecan 4 is required on the cell surface for TG2 function. Taken to-
gether with the inhibitory effect of the P1 peptide, which mimics the
syndecan-4 binding domain within the TG2 molecule [8], and which
can be rescued through the addition of exogenous TG2, these data sup-
port the notion that cell surface TG2, in associationwithHSof syndecan-
4 mediates MØ–AC interaction. Sequential knockdown of syndecan-4
expression and inhibition of TG2 activity together showed no further re-
duction in AC clearance suggesting TG2 exerts most, if not all of its cell
surface effects on AC clearance through its associationwith syndecan-4.
Interaction of cell surface adhesion molecules either with ECM
components or neighbouring cells are known to inﬂuence cell behav-
iour including phagocytosis. CD44, a principal surface receptor for the
ECM molecule hyaluronan (a well-known cell–cell and cell–matrix in-
teraction mediator), is known for recruiting monocytes to sites of in-
ﬂammation [45] and is implicated in AC clearance [46]. Furthermore
CD44, an HSPG, is a known phagocytic receptor [38] that, when
cross-linked experimentally by antibody augments AC clearance by
an, as yet, incompletely deﬁned mechanism [20]. In light of these
pieces of information, we hypothesised that TG2 might modulate
AC clearance bymediating CD44 cross-linking to promote AC clearance.
Co-immunoprecipitation studies revealed an interaction between TG2
and CD44 but this may be a direct or indirect interaction. CD44
was also detected at the MØ cell surface and was detected in TG2-
expressing MØ (THP-derived or HMDMØ) as two distinct molecular
weight bands. CD44 exists in variant isoforms as a result of alternative
splicing or variable N- and O-linked glycosylation [36,47,48]. CD44 is
the most prevalent form (40 kDa) and with extensive post-translation
glycosylation can increase in mass (80 kDa) [49,50]. Notably, TG2
inhibition with a cell-impermeable inhibitor resulted in reduced high
Fig. 6. TG2 associateswith syndecan-4heparan sulphate side chains andmediatesmacrophage–apoptotic cell interaction. Cell surface activity of TG2, andMØ–AC interactionwas assessed
following treatment of MØ (THP-1/DS) with heparinase II (HepII) or chondroitinase (Chon) as described in the Methods section. (A) TG activity is reduced following treatment with he-
parinase II to remove heparan sulphate chains. (B) Treatment of MØwith heparinase II also resulted in signiﬁcant loss of MØ interaction with AC. (C)Western blot analysis of TG2 (whole
cell TG2 or cell surface TG2 isolated following cell surface biotinylation and Neutr-Avidin isolation of cell surface components) inMØ (THP/DS) cells transfected with syndecan-4 speciﬁc
siRNAor a non-speciﬁc (NS) siRNA. This reveals a loss of cell surface (but notwhole cell) TG2when syndecan-4 expression is reduced. (D) Following siRNA-mediated syndecan-4 knockdown
in MØ (THP/DS) with the indicated siRNA constructs, cell surface TG2 activity was assessed and shows a loss of cell surface TG activity. (E) Syndecan-4 knockdown with siRNA (construct
siRNA 2) in MØ (THP/DS) was undertaken prior to assessing MØ–AC interaction. Addition of R281 was also included (for 1 h prior to co-culture and throughout the co-culture period) to
assess additive effects. (F) MØ (THP-1/DS) treated with P1 peptide for 1 h prior to co-culture and throughout the co-culture period (P1; which competes with the heparin binding domain
within the TG2) butnot a scrambled P1 peptide (P1s) show reduced interactionwith AC, that is rescuedwhen200ngpuriﬁed exogenousTG2 (exoTG2) is added.Data shownaremean±S.E.
for n ≥ 3 independent replicates. Statistical analysis was conducted using ANOVA followed by Bonferroni post-test (***P b 0.001).
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CD44. Biotin cadaverine incorporation by cell surface TG2 and subse-
quent pulling down of labelled substrates with Neutr-Avidin and prob-
ing for CD44 on western blot showed high and low molecular weight
CD44 but a loss of highmolecular weight CD44was evident upon treat-
ment with TG2 inhibitor R281 prior to biotin-cadaverine incorporation.
This conﬁrms that in situ CD44 is a potential substrate of MØ–cell
surface TG2. These data suggest that CD44 is a substrate of TG2 and
can be cross-linked by the enzyme via a mechanism requiring its
binding to cell surface HS. This may provide a physiological equivalent
of antibody cross-linking to augment AC clearance by MØ [20]. Taken
together, our data support the hypothesis that TG2 exerts its effect on
AC clearance through the cell surface association with its high afﬁnity
binding partner syndecan-4 and that this may be due, at least in part,
through CD44 cross-linking. However, further work is required toassess the details of this interaction and the subsequent downstream
signalling that results.
MØ–CD44 ligationmediated augmented AC intake is evident in both
in vitro and in vivo [20,51] conditions. Cuff et al. demonstrated that
CD44 promotes MØ recruitment to atherosclerotic lesions (sites of ex-
tensive cell death) [52], while MØ from CD44−/−mice showed delayed
migration into areas of inﬂammation [53] and a defective clearance of
AC [46]. Interestingly, our MØ migration studies revealed reduced
migration and directionality following TG2 inhibition. Taken together
these suggest that TG2, syndecan-4 and CD44 may work together to
mediate migration to and clearance of AC. Such a mechanism for
TG2 involvement in cell migration is not without precedent, since TG2
binding to syndecan-4 has also been implicated in the crosslinking of
cell surface S100A4 resulting in the increased motility of mammary
cancer cells [12].
Fig. 7. TG2 interacts with CD44. (A) Western blot analysis of CD44 in whole cell lysates of THP-1/PMA MØ, THP-1/DS MØ and HMDMØ reveals two distinct molecular weight bands
for CD44. Arrowheads indicate high and low molecular weight bands for CD44. Stripped membranes were re-probed with mouse anti-β-actin antibody as a loading control. (B) MØ
(THP/DS) were treated with the indicated TG2 inhibitors for 1 h prior to cell lysis and western blot analysis for CD44. Upper panel: A representative blot showing a signiﬁcant loss in
highmolecular CD44 (~150–160 kDa) and an increase in the intensity of lowmolecular weight CD44 (~85–95 kDa) in comparison to untreatedMØ. Strippedmembranes were re-probed
with anti-β-actin antibody as a loading control. Lower panel shows the ratio of the high:low molecular weight bands assessed by densitometry from three independent experiments
(mean ± S.E.). Data shown were normalised to the signal fromMØ alone. (C) Immunoprecipitation of TG2 frommembrane lysates of THP-1/DS MØ and primary HMDMØ cells was un-
dertaken and probed on western blot for CD44. This reveals an interaction between TG2 and CD44 proteins. (D) Upper panel: western blot analysis of CD44 from immunoprecipitates of
TG2 following inhibition of TG2with R281 inHMDMØ (representative blot); the lower panel shows the ratio of the high:lowmolecularweight bands assessed by densitometry from three
independent experiments (mean ± S.E.). Arrowheads indicate high and low molecular weight bands for CD44. HC indicates heavy chain and LC indicates light chain. Statistical analysis
was conducted using ANOVA followed by Dunnett's post-test (*P b 0.05; **P b 0.01, ***P b 0.001).
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sulphates (e.g. on syndecan 4, CD44 and potentially other molecules),
which are required for its translocation to the MØ cell surface, may
provide the platform for TG2's interactionwith a range of other cell sur-
face molecules to mediate a range of TG2-mediated functions. Such
functions may include those where the enzyme is brought into contact
with substrates (such as CD44, S100A4 or the large latent TGF-beta
binding proteins) and also other high-afﬁnity binding proteins such as
ﬁbronectin and integrins (β1 and β3), the latter of which are needed
for cell adhesion, migration [40] and phagocytosis [19]. Indeed this
may help to explain the compensatory increase inβ3 integrin expression
as seen in macrophages from TG2−/− animals. To date the molecular
mechanism bywhich CD44-augmented phagocytosis occurs remains
to be elucidated but it has been shown unequivocally to be indepen-
dent of serum opsonins and glucocorticoid-inducedMer-tk/protein Spathway [20]. CD44 crosslinking has been suggested to stabilise
AC–MØ interactions through an ill-deﬁnedmechanism but the propos-
al that CD44 is a substrate for TG2 raises the possibility of a functional
link between CD44 and the established role of TG2 in the development
of phagocytic portals [19].
In conclusion, we demonstrate that TG2 associates with HS during
its translocation to the cell surface of human macrophages. At this site,
in association with syndecan-4, its crosslinking activity is central for it
to exert its effect on AC removal, at least in part, by promoting the
tethering of AC. However TG2 is also involved in human MØmigration
to dying cells, raising the possibility that TG2 inhibitors may be used
to modulate MØ migration for therapeutic gain, in those situations
where MØ migration to dying cells is not beneﬁcial. We further reveal
a novel TG2–CD44 interaction and demonstrate that CD44 is a potential
substrate of TG2 and that inhibition of TG2 activity reduces high
Fig. 8.CD44 acts as a substrate for TG2 inmediating apoptotic cell clearance. (A) THP-1/DS
MØ was exposed, in the presence or absence of TG2 inhibitor R281, to biotin-cadaverine
(BTC) as ameasure of cell surface TG2 activity.Where R281was used,MØwas pre-treated
with an inhibitor for 1h prior to the addition of BTC. Following BTC incorporation, cell lysates
of THP-1/DSMØwere subject to pulldown of biotin-containing molecules by Neutr-Avidin-
Agarose resin beads. The pulldowns were probed by western blotting for CD44 to reveal
TG2-mediated BTC incorporation into CD44. This reveals incorporation of biotin-cadaverine
into CD44 proteins in TG2 expressing cells and reduced incorporation upon treatment with
non-permeable TG2 inhibitor R281. Arrowheads indicate high and low molecular weight
bands for CD44. A signiﬁcant loss in high molecular CD44 (~150–160 kDa) in comparison
to untreated MØ is shown. (B) cell surface TG2 (red) and CD44 (green) on the MØ cell sur-
facewere stained by indirect immunoﬂuorescence, incubating live cellswith rabbit anti-TG2
and mouse anti-CD44 primary antibodies. Cells were further stained with a secondary re-
agent (anti-rabbit-PE; anti-mouse-FITC). TG2 co-localizes with CD44 on theMØ cell surface
(MERGE/yellow). Staining is visualized by confocal microscopy. (C) CD44 and/or SDC4
knockdownwith siRNA inMØ (THP/DS) was undertaken prior to assessingMØ–AC inter-
action. Addition of R281 was also included to assess additive effects. Data shown are
mean ± S.E. For n ≥ 3 independent replicates. Statistical analysis was conducted using
ANOVA followed by Bonferroni post-test (***P b 0.001).
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augmenting AC clearance at least in part through CD44 cross-linking.
This is entirely compatible with established ability of TG2 to function
with MFG-E8 and β3 integrin to remove AC and mediate its uptake via
signalling the recruitment of the CrkII–DOCK180–Rac1 complex and
thus activating GTPase Rac1 [21]. Further work is now needed to assess,
in detail, the importance of CD44–TG2 interactions to AC clearance and
to deﬁne the nature of the TG2-mediated high molecular mass com-
plexes that result.
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doi.org/10.1016/j.bbamcr.2014.09.020.Acknowledgements
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